21 Biopolis Road
No. 04-24/28 Nucleos South Building
Singapore 138567
Singapore
65 6924 6535
https://www.prestigebiopharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Ms. So-Yeon Park | Chairman & CEO | N/A | N/A | 1963 |
Mr. Lai Wat Tay | CFO & Director | N/A | N/A | 1956 |
Mr. Michael Jinwoo Kim | COO & Director | N/A | N/A | 1964 |
Ms. Chung Shii Hii | Chief Technology Officer | N/A | N/A | 1979 |
Ms. Kay K.H. Lee | Clinical Development Manager | N/A | N/A | 1970 |
Mr. Ghislain M.C Bonamy | General Manager of Licensing | N/A | N/A | 1979 |
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. The company primarily engages in the development of biosimilars, including Trastuzumab, which is under regulatory review for breast and gastric cancer; Bevacizumab, in phase 3 clinical study for solid tumours; Adalimumab, in phase 1 clinical study for arthritis. It is developing first-in-class antibody therapeutics, such as monoclonal antibodies, bispecific antibodies, and fusion antibodies for life-threatening diseases; vaccines for COVID-19 virus; and diagnostic kits for the detection of pancreatic adenocarcinoma upregulated factor. Prestige BioPharma Limited was incorporated in 2015 and is headquartered in Singapore.
Prestige BioPharma Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.